Our results are consistent with a previous study on the increased expression of IL1-RI in in vitro-differentiated Th17 mouse cells (12), as well as with our previously published study reporting higher IL-1R protein expression in IL-17A+CD4+ (Th17) cells in comparison to IFN-γ+CD4+ (Th1) and IL-4+CD4+ (Th2) cells from CIS patients (23). This evidence concerns the gene IL1R1 and in situ carcinoma.